|
Acquisition
Veeda Oncology Acquires Biologie et Industries
The acquisition is a big boost to increase its global presence
within the oncology CRO marketplace
Veeda Oncology, the subsidiary of one of the leading Global CRO's in India,
Veeda Clinical Research, has completed the acquisition of Biologie et Industrie
(B&I), an Oncology CRO founded in 1984, based in Paris, France. The acquisition
of B&I, with over 20 years of oncology CRO experience, significantly complements
Veeda Oncology's capability within mainland Europe.
Announcing the acquisition, Binoy Gardi, Co-Managing Director of the Veeda Group,
said, "The acquisition of B&I is one significant pillar that we are
adding to our global oncology presence within the oncology CRO marketplace."
Gardi added, "The clients of B&I will now be able to enjoy the strong
global oncology patient accrual ability that currently exists within Veeda Oncology
as well as the other full service capabilities that Veeda Oncology provides
to their clients."
Veeda Oncology is a global oncology CRO with operations in India, Eastern Europe,
Western Europe and the US. The company is a full service oncology CRO for Phase
I through Phase IV studies with the unique capability of providing rapid and
strong global patient accrual with an effective cost structure. Veeda Oncology
feels that the acquisition of B & I truly strengthens Veeda Oncology's capabilities.
Dr Rémy Brossel, MD, B&I and Dr Sylvie Brossel, MD, B & I, will
both remain with the company to lead the operations within Europe. Said Dr Rémy
Brossel, "It will allow B&I to participate in the global environment
for oncology clinical trials for our clients and to add greatly to the capacity
that we can provide our clients. Now, we can effectively provide access to patients
in the US, Eastern Europe, India as well as central Europe."
Matt Bowman, President and CEO of Veeda Oncology, said, "The addition of
both Dr Remy and Dr Sylvie Brossel from B&I will have a great impact on
our European presence. Combining this with our organisation in Gorlitz, Germany
allows for significant growth potential within the European market. In addition,
all our global clients will benefit from the 20 years of oncology expertise
that B&I will bring to Veeda."
EH News Bureau
|
